Royal D S M Nv ADR (RDSMY) 18.4000 $RDSMY
Cimarex Reports Fourth-Quarter and Full-Year 2013 Results (unaudited)
PR Newswire - Wed Feb 19, 7:00AM CST
Cimarex Energy Co. (NYSE: XEC) today reported adjusted fourth-quarter 2013 net income of $117.6 million, or $1.35 per diluted share, compared to fourth-quarter 2012 adjusted net income of $102.8 million, or $1.19 per diluted share(1). For the year, adjusted net income totaled $469.3 million, or $5.38 per diluted share, as compared to 2012 adjusted net income of $366.8 million, or $4.22 per diluted share. See attached table to the financial statements for a full reconciliation of adjusted net income.
OTC Markets Group Reports 2013 Trading Statistics and Highlights
PR Newswire - Wed Jan 29, 9:17AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced its trading statistics and highlights for 2013 as well as its plans for 2014.
DSM Begins Trading on OTCQX®
PR Newswire - Tue Aug 06, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that DSM (OTCQX: RDSMY; NYSE Euronext: DSM), a global science-based company active in health, nutrition and materials, has chosen to have its American Depositary Receipts (ADRs) traded on OTCQX®, the best marketplace with qualified companies.
DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
PR Newswire - Mon Apr 22, 1:00AM CDT
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA
DSM announces June opening of new cGMP biopharmaceutical manufacturing operation in Brisbane, Australia
PR Newswire - Mon Apr 22, 1:00AM CDT
The DSM facility was built with cooperation from the Queensland and Commonwealth Governments of Australia. Karen King, President of DSM Biologics, the biopharmaceutical manufacturing business of DSM Pharmaceutical Products, stated, "We are thrilled to announce the June opening of our new cGMP facility in Brisbane. This operation combines DSM's twenty five years of experience and high quality track record in mammalian cell culture manufacturing with a state-of-the-art commercial and development facility. Our partnership with the Government of Queensland and the Commonwealth of Australia has led to this important addition to the Australian biotechnology industry and will be a key contributor to the entire Asia-Pacific region."
Presentations From Deutsche Bank's Depositary Receipts Virtual Investor Conference Now Available for On-demand Viewing
PR Newswire - Thu Mar 28, 7:30AM CDT
Deutsche Bank Depositary Receipts today announced that the archive presentations from their March 19 virtual investor conference are now available for 24/7 viewing. Nine publicly-listed global companies, presented and answered questions live.
International Companies to Host Live Webcasts at Deutsche Bank's March 19 Depositary Receipts Virtual Investor Conference
CNW Group - Wed Mar 13, 4:33PM CDT
Deutsche Bank Depositary Receipts today announced the line-up of its March 19 virtual investor conference, featuring live presentations from nine international companies. Company representatives will respond to questions in real-time during formal presentations and will also interact with investors in virtual trade booths. The conference is primarily targeted to the individual retail investor but is also open to institutional investors and analysts.
DSM signs Master Supply Agreement with Eisai Inc.
PR Newswire - Tue Mar 05, 1:00AM CST
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE/Euronext: DSM KON), today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products. The agreement covers the production of eribulin mesylate as well as other developmental drugs. Alexander Wessels, President and CEO of DSM Pharmaceutical Products, stated, "We are delighted to be working with Eisai under a long-term agreement to serve markets globally for important human health treatments, bringing our expertise and reliability in sterile injectables and worldwide regulatory record to ensure market supply."
DSM announces license agreement with Amgen for use of DSM's
® Cell Culture Patents
PR Newswire - Tue Jan 15, 1:00AM CST
Karen King, President of DSM Biologics, commented "We are pleased to enter into this license agreement with Amgen, a global leader in biopharmaceutical drug development and manufacturing. We believe our proprietary® technology will play an important role in the next generation of biopharmaceutical manufacturing." ® technology is a highly intensified cell culture process with typical titer achievement of 8-to-10 times higher compared to current standard biomanufacturing processes. For some products, titer improvements of up to 15 times have been achieved. It is widely applicable for multiple biological products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems.
Cimarex Reports Fourth-Quarter and Full-Year 2013 Results (unaudited)
PR Newswire - Wed Feb 19, 7:00AM CST
Cimarex Energy Co. (NYSE: XEC) today reported adjusted fourth-quarter 2013 net income of $117.6 million, or $1.35 per diluted share, compared to fourth-quarter 2012 adjusted net income of $102.8 million, or $1.19 per diluted share(1). For the year, adjusted net income totaled $469.3 million, or $5.38 per diluted share, as compared to 2012 adjusted net income of $366.8 million, or $4.22 per diluted share. See attached table to the financial statements for a full reconciliation of adjusted net income.
OTC Markets Group Reports 2013 Trading Statistics and Highlights
PR Newswire - Wed Jan 29, 9:17AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced its trading statistics and highlights for 2013 as well as its plans for 2014.
DSM Begins Trading on OTCQX®
PR Newswire - Tue Aug 06, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that DSM (OTCQX: RDSMY; NYSE Euronext: DSM), a global science-based company active in health, nutrition and materials, has chosen to have its American Depositary Receipts (ADRs) traded on OTCQX®, the best marketplace with qualified companies.
DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
PR Newswire - Mon Apr 22, 1:00AM CDT
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA
DSM announces June opening of new cGMP biopharmaceutical manufacturing operation in Brisbane, Australia
PR Newswire - Mon Apr 22, 1:00AM CDT
The DSM facility was built with cooperation from the Queensland and Commonwealth Governments of Australia. Karen King, President of DSM Biologics, the biopharmaceutical manufacturing business of DSM Pharmaceutical Products, stated, "We are thrilled to announce the June opening of our new cGMP facility in Brisbane. This operation combines DSM's twenty five years of experience and high quality track record in mammalian cell culture manufacturing with a state-of-the-art commercial and development facility. Our partnership with the Government of Queensland and the Commonwealth of Australia has led to this important addition to the Australian biotechnology industry and will be a key contributor to the entire Asia-Pacific region."
Presentations From Deutsche Bank's Depositary Receipts Virtual Investor Conference Now Available for On-demand Viewing
PR Newswire - Thu Mar 28, 7:30AM CDT
Deutsche Bank Depositary Receipts today announced that the archive presentations from their March 19 virtual investor conference are now available for 24/7 viewing. Nine publicly-listed global companies, presented and answered questions live.
International Companies to Host Live Webcasts at Deutsche Bank's March 19 Depositary Receipts Virtual Investor Conference
CNW Group - Wed Mar 13, 4:33PM CDT
Deutsche Bank Depositary Receipts today announced the line-up of its March 19 virtual investor conference, featuring live presentations from nine international companies. Company representatives will respond to questions in real-time during formal presentations and will also interact with investors in virtual trade booths. The conference is primarily targeted to the individual retail investor but is also open to institutional investors and analysts.
DSM signs Master Supply Agreement with Eisai Inc.
PR Newswire - Tue Mar 05, 1:00AM CST
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE/Euronext: DSM KON), today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products. The agreement covers the production of eribulin mesylate as well as other developmental drugs. Alexander Wessels, President and CEO of DSM Pharmaceutical Products, stated, "We are delighted to be working with Eisai under a long-term agreement to serve markets globally for important human health treatments, bringing our expertise and reliability in sterile injectables and worldwide regulatory record to ensure market supply."
DSM announces license agreement with Amgen for use of DSM's
® Cell Culture Patents PR Newswire - Tue Jan 15, 1:00AM CST
Karen King, President of DSM Biologics, commented "We are pleased to enter into this license agreement with Amgen, a global leader in biopharmaceutical drug development and manufacturing. We believe our proprietary
® technology will play an important role in the next generation of biopharmaceutical manufacturing." ® technology is a highly intensified cell culture process with typical titer achievement of 8-to-10 times higher compared to current standard biomanufacturing processes. For some products, titer improvements of up to 15 times have been achieved. It is widely applicable for multiple biological products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems. 
